Abstract
Primary antiphospholipid syndrome (APS) is a disease characterized by the presence of autoantibodies reacting with proteins bound to phospholipids, leading to thrombosis and gestation abnormalities. Prothrombotic states and impaired clot dissolution are believed to contribute to the occurrence of chronic thromboembolic pulmonary hypertension (CTEPH) in APS. Whether preventive anticoagulation therapy in patients with antiphospholipid autoantibodies without a history of thrombosis reduces the risk of thrombosis is currently unclear. The diagnosis and treatment of CTEPH in APS is similar to CTEPH complicated by other predisposing conditions, with surgical treatment being the most effective. However, not every patient with CTEPH is suitable for pulmonary thromboendartarectomy and such individuals may benefit from pharmacotherapy of pulmonary hypertension, given the presence of pulmonary microvascular abnormalities similar to those in idiopathic pulmonary hypertension. Anticoagulation therapy is the mainstay of management because of the high risk of recurrent embolization and local in-situ thrombosis.
Keywords: Antiphospholipid syndrome, pulmonary hypertension, thrombosis, pulmonary embolism.
Current Pharmaceutical Design
Title:Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Volume: 20 Issue: 4
Author(s): Aibek E. Mirrakhimov and Nicholas S. Hill
Affiliation:
Keywords: Antiphospholipid syndrome, pulmonary hypertension, thrombosis, pulmonary embolism.
Abstract: Primary antiphospholipid syndrome (APS) is a disease characterized by the presence of autoantibodies reacting with proteins bound to phospholipids, leading to thrombosis and gestation abnormalities. Prothrombotic states and impaired clot dissolution are believed to contribute to the occurrence of chronic thromboembolic pulmonary hypertension (CTEPH) in APS. Whether preventive anticoagulation therapy in patients with antiphospholipid autoantibodies without a history of thrombosis reduces the risk of thrombosis is currently unclear. The diagnosis and treatment of CTEPH in APS is similar to CTEPH complicated by other predisposing conditions, with surgical treatment being the most effective. However, not every patient with CTEPH is suitable for pulmonary thromboendartarectomy and such individuals may benefit from pharmacotherapy of pulmonary hypertension, given the presence of pulmonary microvascular abnormalities similar to those in idiopathic pulmonary hypertension. Anticoagulation therapy is the mainstay of management because of the high risk of recurrent embolization and local in-situ thrombosis.
Export Options
About this article
Cite this article as:
Mirrakhimov E. Aibek and Hill S. Nicholas, Primary Antiphospholipid Syndrome and Pulmonary Hypertension, Current Pharmaceutical Design 2014; 20 (4) . https://dx.doi.org/10.2174/138161282004140213125951
DOI https://dx.doi.org/10.2174/138161282004140213125951 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interaction of Cyclosporine A and the Renin-Angiotensin System New Perspectives
Current Drug Metabolism Is Metabolic Syndrome X a Disorder of the Brain?
Current Nutrition & Food Science Could Better Phenotyping Small Vessel Disease Provide New Insights into Alzheimer Disease and Improve Clinical Trial Outcomes?
Current Alzheimer Research Targeting Conserved Pathways: Mitochondrial Dysfunction and Beyond
Current Neurovascular Research Monitoring and Surveillance of Obesity in the United States
Current Nutrition & Food Science Telmisartan Blocks Advanced Glycation End Product (AGE)-Induced Plasminogen Activator Inhibitor-1 (PAI-1) Gene Expression in Endothelial Cells via Activation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ )
Letters in Drug Design & Discovery Biochemical, Enzymatic and Molecular Properties of Renin/Prorenin Mediated by (Pro)Renin Receptor
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Novel Biginelli-Like Reaction: An Efficient One-pot Synthesis of Spiro[oxindole-quinazoline/pyrimidine]ones
Letters in Organic Chemistry Obesity and Oxidative Stress: Potential Roles of Melatonin as Antioxidant and Metabolic Regulator
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Editorial [Hot Topic: Structural-Functional Studies of Animal Toxins (Guest Editor: Marcos R.M. Fontes)]
Protein & Peptide Letters Chronic Kidney Disease and the Risk of Cardiovascular Disease Events: A Community-Based Approach
Vascular Disease Prevention (Discontinued) “Self-Nonself” Peptides in the Design of Vaccines
Current Pharmaceutical Design α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Vascular Dysfunction in the Brain; Implications for Heavy Metal Exposures
Current Hypertension Reviews Role of Adipokines and Cytokines in Non-alcoholic Fatty Liver Disease
Reviews on Recent Clinical Trials Potential Role of Polyphenols in the Prevention of Cardiovascular Diseases: Molecular Bases
Current Medicinal Chemistry Synthesis and Binding Properties of New Endothelin Receptor Ligands
Letters in Drug Design & Discovery Targeting Vascular Endothelial Growth Factor Pathway in First-Line Treatment of Metastatic Colorectal Cancer: State-of-the-Art and Future Perspectives in Clinical and Molecular Selection of Patients
Current Cancer Drug Targets Microalbuminuria In Primary Hypertension
Current Hypertension Reviews